ACC and AHA release updated cholesterol management guidelines

The American College of Cardiology and American Heart Association have issued new guidelines on cholesterol screening and management, urging earlier testing and personalized risk assessments. The recommendations, presented on March 28 in New Orleans, emphasize lowering LDL cholesterol and incorporating genetic factors like lipoprotein(a). A new risk calculator aims to predict heart disease over longer periods.

The guidelines, the first update since 2018, were published in the Journal of the American College of Cardiology and Circulation. They were unveiled at the American College of Cardiology's 75th Annual Scientific Session in New Orleans. Roger S. Blumenthal, chair of the writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, stated, 'We know that lower LDL cholesterol levels are better when it comes to reducing the risk of heart attacks, strokes and congestive heart failure.' The guidance stresses lifestyle changes as the foundation, noting that 80% to 90% of cardiovascular disease links to modifiable factors like diet, exercise, and weight control. About one in four U.S. adults has elevated LDL cholesterol, which contributes to atherosclerosis and potential heart events. Doctors are now advised to screen earlier, such as from age 9 for those with familial hypercholesterolemia, and perform a one-time Lp(a) test, which elevates risk by 40% at certain levels. The new PREVENT calculator estimates 10- and 30-year risks starting at age 30, drawing from data on 6.6 million people and including kidney function and blood sugar. Seth Martin, a cardiologist on the committee, said, 'Shifting the paradigm toward proactive prevention strategies earlier in life can meaningfully change the trajectory of cardiovascular disease.' For treatment, optimal LDL targets range from below 100 mg/dL for low-risk individuals to under 55 mg/dL for high-risk ones, with options like statins, ezetimibe, and PCSK9 inhibitors. Risk enhancers such as coronary artery calcium scans and inflammation markers help tailor plans.

Related Articles

Scientific illustration of HELZ2 protein in the liver regulating cholesterol release.
Image generated by AI

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

Reported by AI Image generated by AI Fact checked

Scientists at UT Southwestern Medical Center report they have identified a protein, HELZ2, that acts as a key regulator of how many cholesterol-carrying particles the liver releases into the bloodstream by affecting the gene APOB. The study was published in the American Heart Association journal Circulation and could inform future research into heart disease and fatty liver disease.

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

Reported by AI

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline